Category: European Patent Office
-
EPO sets out six priorities for strengthening Europeâs technology transfer
A new EPO study of over 800 technology transfer offices reveals that European universities now own as many patents as their U.S. counterparts, but with a fraction of the commercialization capacity. The gap between ownership and impact is widening, and the report lays out six priorities for closing it.
-
UPC’s CD Milan assumes jurisdiction over declaratory judgment concerning future divisionals and over anti-abandonment injunctions
The UPC’s CD Milan has taken an expansive stance on declaratory and injunctive relief for the purpose of thwarting the so-called divisional game, but has also recognized the need for appellate guidance.
-
China, Hong Kong-based defendants now account for roughly one-third of new UPC infringement and PI cases
Chinese and Hong Kong-based defendants now account for about a third of new UPC infringement and PI cases and face above-average injunction rates, as the UPC stays few cases pending EPO oppositions.
-
EPO board of appeal rejects claim-saving approach to ambiguous amendments
The EPO Board of Appeal has rejected a claim-saving approach to ambiguous amendments in a Philip Morris e-cigarette patent dispute, holding that unresolved ambiguity can broaden a claim and create added-matter problems.Â
-
EPO Enlarged Board limits mandatory description amendments in G 1/25
The EPO Enlarged Board of Appeal has ruled that amended claims do not automatically require corresponding changes to the description, while reinforcing the descriptionâs role in claim interpretation.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent CourtÂ
The Munich I Regional Court has found that Accord infringed TOWAâs dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.
-
EWHC hinders Accordâs plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accordâs âattacksâ on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendantâs supplementary protection certificate.
-
âThe future of medicine and diagnosticsâ: behind the patent enforcement strategy of biotech tools company SeerÂ
Seerâs VP of Legal, George Fox, discusses the challenges that its patent portfolio has recently overcome, and the enforcement campaign it has launched in the U.S.Â
-
EPO appellate ruling highlights uncertainty over need to address all auxiliary requests
A newly published EPO appeal decision supports allowing opponents to defer arguments against unexamined auxiliary requests, highlighting continuing uncertainty in Board of Appeal case law.
-
EPO board of appeal refers major claim-construction, added-matter, and referral questions to Enlarged Board of Appeal
A Technical Board of Appeal 3.3.05 has referred fundamental questions on claim interpretation and added matter to the Enlarged Board of Appeal, while also asking whether the EBAâs traditionally restrictive approach to accepting referrals should be reconsidered.